Clinical trials: Carcinomas
Non Small Cell Lung Cancer (NSCLC), Melanoma (Skin Cancer)
Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis
The NeutroFlow study is a multi-center clinical trial designed to develop a computational model that converts flow cytometry results into a prediction of clinical benefit.
- Conditions
- Non Small Cell Lung Cancer (NSCLC), Melanoma (Skin Cancer), Triple Negative Breast Cancer (TNBC), RCC, Renal Cell Cancer
- Trial name
- NEUTROFLOW (NCT07246759)
- Testing
- Blood sample collection
- Where
- 3 sites in Germany, Italy and 1 more
- Volunteers
- 600 people
- Sponsor
- OncoHost Ltd.
Potentially Resectable Hepatocellular Carcinoma
A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma
This is a single term, open label, single Center, Phase II Trial. The study is to explore the efficacy and safety of FOLFOX-HAIC combined with Lenvatinib and Envolizumab in the treatment of patients with potentially resectable…
- Trial name
- NCT06143579
- Testing
- FOLFOX-HAIC+Lenvatinib+Envolizumab
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Epithelial Ovarian Cancer
[18F]Fluoro-PEG-folate PET/CT Imaging in Epithelial Ovarian Cancer
The pre-operative assessment of intra-abdominal tumor load in patients with epithelial ovarian cancer (EOC) remains unreliable with standard imaging modalities.
- Trial name
- NCT05215496
- Testing
- [18F]fluoro-PEG-folate PET/CT scan
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Lioe-Fee de Geus-Oei, MD PhD
Medullary Thyroid Cancer
A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
A study to evaluate the efficacy and safety of pralsetinib compared with SOC treatment (cabozantinib or vandetanib) for participants with RET (rearranged during transfection)-mutant MTC who have not previously received a SOC…
- Trial name
- AcceleRET-MTC (NCT04760288)
- Testing
- Pralsetinib, Cabozantinib, Vandetanib
- Where
- Spain
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)
This is a Phase II, double-blind, randomized, multicenter trial designed to preliminarily evaluate the activity and safety of treatment with MetMAb + erlotinib versus erlotinib + placebo in second- and third-line Non-Small Cell…
- Trial name
- NCT00854308
- Testing
- Erlotinib HCl, MetMAb
- Volunteers
- 137 people
- Sponsor
- Genentech, Inc.
Primary Liver Cancer
Chinese Liver Cancer Clinical Survey
In order to make better use of clinical resources of the real world, strengthen the standardization of PLC diagnosis and treatment, and constantly improve the academic level of liver cancer in China, we intends to launch "Chinese…
- Trial name
- CLCS (NCT03161925)
- Volunteers
- 5,000 people
- Sponsor
- Beijing Insight Science & Technology Co. Ltd.
Extensive Stage Small Cell Lung Cancer
The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer
This trial will investigate the addition of an antibody (Ipilimumab) to conventional Carboplatin and Etoposide chemotherapy in extensive stage small cell lung cancer.
- Trial name
- ICE (NCT01331525)
- Testing
- Ipilimumab
- Where
- 7 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Urothelial Carcinoma
Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma
This study plans to learn more about the combination of AMG 386 and docetaxel for the treatment of advanced urothelial cancer. Subjects are being asked to be in this research study because they have advanced urothelial cancer…
- Trial name
- NCT01907308
- Testing
- AMG 386, Docetaxel
- Sponsor
- University of Colorado, Denver
Posto Perative Hepatocellular Carcinoma
Clinical Study of mRNA Vaccine in Patients With Liver Cancer After Operation
This is an open, one-arm study to evaluate the safety and efficacy of mRNA personalized tumor vaccine (tumor vaccine) encoding neonatal antigen in combination with Sintilimab injection for adjuvant prevention of postoperative…
- Trial name
- NCT05761717
- Testing
- Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I njection
- Volunteers
- 67 people
- Sponsor
- Shanghai Zhongshan Hospital
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002717
- Testing
- cisplatin, paclitaxel
- Where
- 52 sites in United States
- Volunteers
- 324 people
- Sponsor
- Gynecologic Oncology Group
Head and Neck Cancer
Anti-platelet + Pembro for H&N Tumors
The purpose of this study is to see if anti-platelet therapy combined with anti-PD-1 immunotherapy can cause a more favorable immunologic response thatn with immunotherapy alone in patients with recurrent or metastatic squamous…
- Trial name
- NCT03245489
- Testing
- Pembrolizumab, Clopidogrel, acetylsalicylic acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical University of South Carolina
Non-small Cell Lung Cancer, Non-small Cell Carcinoma
Investigating the Feasibility of a Physical Activity (tele)coaching Intervention in Patients with Non-small Cell Lung Cancer: an Explorative Study
The aim of this study is to investigate the acceptability, actual usage, feasibility and safety of 1) a (semi) automated PA tele coaching intervention including smartphone application and stepcounter (Fitbit Charge 4) and 2) a…
- Trial name
- LUCA-coach (NCT05569291)
- Testing
- Automated Coaching Program (ACP), Manual Coaching Program (MCP)
- Where
- 2 sites in Belgium
- Volunteers
- 19 people
- Sponsor
- Hasselt University
Oropharyngeal Squamous Cell Carcinoma
Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma
Pembrolizumab and nivolumab (with or without chemotherapy) are used to treat head and neck cancer. The middle part of the throat (oropharynx) is a common location for head and neck cancer.
- Trial name
- NCT06771674
- Testing
- Pembrolizumab, Nivolumab
- Where
- United States
- Volunteers
- 662 people
- Sponsor
- Hookipa Biotech GmbH
Prostate Carcinoma
Building Community Living Labs in Black Communities to Advance Prostate Health Equity and Reduce Prostate Cancer Disparities in Black Men
This clinical trial the possibility of establishing a Community Living Labs (CoLLab) Learning Health System to facilitate access to prostate health Risk, Education, and Assessment in the Community with Help (REACH) services in…
- Trial name
- CoLLab (NCT06541210)
- Testing
- Community Health Service, Questionnaire Administration
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Hepatocellular Carcinoma, Atezolizumab Plus Bevacizumab
Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma
This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of low-dose bevacizumab plus atezolizumab combined with transarterial chemoembolization followed by hepatic arterial infusion…
- Conditions
- Hepatocellular Carcinoma, Atezolizumab Plus Bevacizumab, Transarterial Chemoembolization
- Trial name
- NCT07543510
- Testing
- TACE-HAIC + Atezolizumab + Low-dose Bevacizumab
- Volunteers
- 38 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Carcinoma, Hepatocellular
Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)
This was a multicenter, randomized, double-blind, phase III trial. This clinical study evaluates the efficacy and safety of Apatinib in patients with advanced liver cancer who have progressed on Systemic Therapy (Chemotherapy…
- Trial name
- NCT02329860
- Testing
- Apatinib
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate
RYZ711 Diagnostic Platform Study
This is a Phase 1/2 multicenter, multi-cohort imaging study to evaluate the safety, tolerability, and diagnostic performance of RYZ711 positron emission tomography/computed tomography (PET/CT) in men with histologically confirmed…
- Conditions
- Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Trial name
- NCT07862582
- Testing
- RYZ711, PSMA PET/CT
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- RayzeBio, Inc.
Nasopharyngeal Neoplasms, Radiodermatitis
Comparison of Efficacy and Safety Between Medical Radiation Protectants (FORRAD®) and Trolamine (Biafine) for the Management of Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma Receiving IMRT
Radiation therapy remains the principal treatment for nasopharyngeal carcinoma (NPC). Although intensity modulated radiation therapy (IMRT) has been widely used in China nowadays, radiation dermatitis is still common.
- Trial name
- NCT02729324
- Testing
- Medical Radiation Protectants (FORRAD®), Trolamine (Biafine)
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Yun-fei Xia
Organ Preservation, Rectal Cancer
Organ Preservation in Rectal Cancer: Contact X-ray Brachytherapy vs Extending the Waiting Interval and Local Excision
The goal of this prospective phase II feasibility study is to evaluate two additional local treatment options in rectal cancer patients with a good clinical response after neoadjuvant (chemo)radiation: contact x-ray brachytherapy…
- Conditions
- Organ Preservation, Rectal Cancer, Quality of Life, Locally Advanced Rectal Carcinoma
- Trial name
- OPAXX (NCT05772923)
- Testing
- Contact x-ray brachytherapy, Local excision
- Where
- 7 sites in Netherlands
- Volunteers
- 168 people
- Sponsor
- The Netherlands Cancer Institute
Hepatocellular Carcinoma (HCC)
The Use of AKR1B10 for Monitoring Postoperative Recurrence of Hepatocellular Carcinoma
Based on the clue that the serum marker AKR1B10 found in the investigators' previous study can be used as an effective indicator for detecting HCC and preHCC, the role and value of AKR1B10 as a new tumor marker for evaluating the…
- Trial name
- NCT06750159
- Testing
- No intervention (observational study)
- Volunteers
- 400 people
- Sponsor
- Peking Union Medical College Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.